Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBS | P35520 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273283 | 0.98 | CBS (0.96) | CBSPTGS2CYP3A4LTA4HTRPV1 | |
| SCHEMBL31546072 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL31545063 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL31545332 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL9472976 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL164545 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL15151838 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL31544858 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL31545757 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE | |
| SCHEMBL31544875 | 0.89 | CBS (0.79) | CBSPTGS2CYP3A4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090081119-A1 | INHIBITING DNA POLYMERASE BETA TO ENHANCE EFFICACY OF ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-03-26 | — | — | US | claimed |
| US-20230040081-A1 | VACCINIA VIRAL POLYMERASE-MEDIATED VIRAL REPLICATION | IMMUNOLUX INTERNATIONAL CORP. | 2023-02-09 | — | — | US | disclosed |
| US-20100048682-A1 | INHIBITING DNA POLYMERASE BETA TO ENHANCE EFFICACY OF ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2010-02-25 | — | — | US | disclosed |
| US-20090081119-A1 | INHIBITING DNA POLYMERASE BETA TO ENHANCE EFFICACY OF ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040081-A1 | VACCINIA VIRAL POLYMERASE-MEDIATED VIRAL REPLICATION | POLR1G, POLR1A, POLR1E | CBS 3857/4885PTGS2 2419/4885CYP3A4 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.